Fundraising Fox
/Companies
Sign in

Alpha Cognition

Vancouver · Founded 2014 · British Columbia, Canada corporation · 1 known investors

Find your way into Alpha Cognition

Sign up to see every warm intro you have to Alpha Cognition

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Alpha Cognition team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Alpha Cognition develops ZUNVEYL (benzgalantamine), a cholinesterase inhibitor approved for treating mild to moderate dementia of the Alzheimer's type in adults. The company operates in the pharmaceutical sector focused on central nervous system and neurodegenerative disease therapeutics.

BiotechDigital Health

Founders & leadership

LD
Lauren D'AngeloNamed on SEC filing
LM
Len MertzNamed on SEC filing
JH
John HavensNamed on SEC filing
MM
Michael McFaddenNamed on SEC filing
JY
Jay YooNamed on SEC filing
RR
Rajeev Rob BakshiNamed on SEC filing
PM
Phillip MertzNamed on SEC filing
KC
Kenneth CawkellNamed on SEC filing
EM
Erich MohrNamed on SEC filing
AM
Alfred MaelickeNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$27.2M disclosed across 15 of 16 rounds · 2016–2024

▶$346.9KofferedNov 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John HavensDirector
  • Michael McFaddenExecutive Officer, Director
  • Phillip MertzDirector
  • Len MertzDirector
  • Henry DuExecutive Officer
  • Lauren D'AngeloExecutive Officer
  • Kenneth CawkellExecutive Officer, Director
  • Rajeev BakshiDirector
Offering amount
$346.9K
First sale
Oct 2024
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedOct 2024 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lauren D'AngeloExecutive Officer
  • Len MertzDirector
  • John HavensDirector
  • Michael McFaddenDirector, Executive Officer
  • Jay YooExecutive Officer
  • Rajeev Rob BakshiDirector
  • Phillip MertzDirector
  • Kenneth CawkellDirector, Executive Officer
Offering amount
$11.1M
Amount sold
$4.5M
Sales commissions
$360.3K
Placement agents
The Benchmark Company, LLC, Spartan Capital Holdings, LLC
First sale
Sep 2024
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJan 2024 · 60 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Len MertzDirector
  • Michael McFaddenExecutive Officer, Director
  • Lauren D'AngeloExecutive Officer
  • John HavensDirector
  • Kenneth CawkellDirector
  • Don KalkofenExecutive Officer
  • Phillip MertzDirector
  • Rob BakshiDirector
Offering amount
$6.8M
Amount sold
$2.8M
Sales commissions
$342.3K
Placement agents
Spartan Capital Securities, LLC
First sale
Jan 2024
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedJan 2024 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Phillip MertzDirector
  • John HavensDirector
  • Kenneth CawkellDirector
  • Michael McFaddenExecutive Officer, Director
  • Len MertzDirector
  • Lauren D'AngeloExecutive Officer
  • Rob BakshiDirector
  • Don KalkofenExecutive Officer
Offering amount
$4.2M
Amount sold
$1.8M
Sales commissions
$238.5K
Placement agents
Spartan Capital Securities, LLC
First sale
Dec 2023
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedNov 2023 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John HavensDirector
  • Len MertzDirector
  • Lauren D'AngeloExecutive Officer
  • Michael McFaddenExecutive Officer, Director
  • Kenneth CawkellDirector
  • Don KalkofenExecutive Officer
  • Phillip MertzDirector
  • Rob BakshiDirector
Offering amount
$1.7M
Amount sold
$1M
Sales commissions
$311.5K
Placement agents
Spartan Capital Securities, LLC
First sale
Nov 2023
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$344KraisedOct 2023 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lauren D'AngeloExecutive Officer
  • Phillip MertzDirector
  • John HavensDirector
  • Len MertzDirector
  • Michael McFaddenExecutive Officer, Director
  • Rob BakshiDirector
  • Don KalkofenExecutive Officer
  • Kenneth CawkellDirector
Offering amount
$586.4K
Amount sold
$344K
Sales commissions
$51.6K
Placement agents
Spartan Capital Securities, LLC
First sale
Oct 2023
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedSep 2023 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John HavensDirector
  • Lauren D'AngeloExecutive Officer
  • Len MertzDirector
  • Kenneth CawkellDirector
  • Rob BakshiDirector
  • Michael McFaddenExecutive Officer, Director
  • Don KalkofenExecutive Officer
  • Phillip MertzDirector
Offering amount
$2.1M
Amount sold
$1.3M
Sales commissions
$180.1K
Placement agents
Spartan Capital Securities, LLC
First sale
Aug 2023
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedMar 2023 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lauren D'AngeloExecutive Officer
  • Len MertzDirector
  • John HavensDirector
  • Rob BakshiDirector
  • Michael McFaddenExecutive Officer, Director
  • Phillip MertzDirector
  • Don KalkofenExecutive Officer
  • Kenneth CawkellDirector
Offering amount
$3.3M
Amount sold
$1.3M
Sales commissions
$172.5K
Placement agents
Spartan Capital Securities, LLC
First sale
Mar 2023
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Alpha Cognition do?
Alpha Cognition develops ZUNVEYL (benzgalantamine), a cholinesterase inhibitor approved for treating mild to moderate dementia of the Alzheimer's type in adults. The company operates in the pharmaceutical sector focused on central nervous system and neurodegenerative disease therapeutics.
Who are Alpha Cognition's investors?
Alpha Cognition's investors include Mertz Holdings.
How much funding has Alpha Cognition raised?
Alpha Cognition has disclosed $27.2M raised across 15 of its 16 known rounds.
Where is Alpha Cognition headquartered?
Alpha Cognition is headquartered in Vancouver.